I lead the team responsible for integrating market insights and data to optimize market tactics, drive revenue, and to deliver, transform, and standardize forecasting capabilities, reporting, and analytics for AZ’s US Oncology portfolio; includes launch prep, characterization of in-line assets, and providing the data foundation for business strategy and field tactics for >$7B of US revenue.Responsible for driving the vision for automation and non-linear scaling of analytics and forecasting capabilities to meet the rapidly expanding needs of the US Oncology Business.

I led insights for multiple US oncology products, spanning multiple solid tumors, and focused on crafting data driven strategy to optimize patient care.Work included leading analytics engagements for new launches (NMEs and new indications), forecasting, competitive intelligence, and data creation to inform and define strategy. Key member of the launch teams for 2 NMEs and multiple line extensions.

I have successfully led >40 in depth client engagements focused on crafting insightful, quantitative strategies to maximize revenue and market adoption. Work has involved:* Product launch planning* Tactical account targeting* Competitive intelligence* Portfolio planning and strategy* Reimbursement and pricing strategies* Long-term product and market forecasting * ROI/trade-off assessments* Investment and acquisition due diligence for >$1B of transactions* Big data and predictive analytics (R, SQL, Python)* Development of social media strategies for life science technologiesThis work has spanned medical devices, pharma and biotech products, digital health, diagnostics, and health system technologies. Areas of specialization include cardiology (structural heart, atrial fibrillation, etc.), robotic and digital surgery, big data and genomic health products, oncology, neurovascular, predictive analytics, and hospital and consumer-facing medical products.I joined Navigant via the acquisition of Dymedex Consulting in 2016.

Conceptualized acute-use ICU medical device, formulated business strategy, recruited executive team and led company through initial venture financing.

Founded to develop the industry leading diagnostic platform for breast and other cancers. Platform received 510K De Novo Clearance in 2017 and is the first FDA approved cancer diagnostic with artificial intelligence/machine learning.Quantitative Insights was successfully acquired in 2019.

Led de novo, need-based creation of diverse therapeutic medical devices [upstream marketing and product definition], with emphasis on neuromodulation technologies; >40 patent applications were filed. Technologies have been licensed by Fortune 500 companies, raised investor capital, and serve as the primary technology of multiple medical device start-ups.

Pairing passionate technology entrepreneurs with investor capital. Crafted investment theses at the intersection of machine learning and life sciences and identified investment opportunities that secured >$75M of investor capital.

Sourced and led investor diligence for >150 seed-stage investment opportunities.

Worked with a successful medical device innovator and entrepreneur to create novel medical devices via a structured needs-based process.

Pre investor-funding team leader at Sutro Biopharma (STRO). 5 years of product and project management experience leading technical and business development teams; critical team member that secured >$35M of VC financing, including Seed and Series A/B financing.

Worked with Dr. Jay Keasling (founder of Amyris, Inc. (AMRS)) and Dr. Jeremy Thorner to develop novel methods for genome-wide mapping of protein-protein interactions.

Explored micro-crystallization and microfluidics with Dr. George Whitesides, Dr. David Weitz, and other leading applied physics and chemistry professors at Harvard University.